• LAST PRICE
    43.6200
  • TODAY'S CHANGE (%)
    Trending Up0.2700 (0.6228%)
  • Bid / Lots
    43.4600/ 4
  • Ask / Lots
    43.7500/ 5
  • Open / Previous Close
    44.9000 / 43.3500
  • Day Range
    Low 43.4300
    High 44.9000
  • 52 Week Range
    Low 15.4401
    High 44.9000
  • Volume
    54,582
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 43.35
TimeVolumeRVMD
09:32 ET2348444.21
09:34 ET545843.61
09:36 ET715543.575
09:38 ET976243.62
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRVMD
Revolution Medicines Inc
7.2B
-11.6x
---
United StatesCERE
Cerevel Therapeutics Holdings Inc
7.5B
-15.1x
---
United StatesCYTK
Cytokinetics Inc
6.5B
-10.5x
---
United StatesVKTX
Viking Therapeutics Inc
6.5B
-62.2x
---
United StatesMDGL
Madrigal Pharmaceuticals Inc
6.2B
-12.7x
---
United StatesSMMT
Summit Therapeutics Inc
6.1B
-51.9x
---
As of 2024-07-12

Company Information

Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Company’s RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.

Contact Information

Headquarters
700 Saginaw DrREDWOOD CITY, CA, United States 94063-4752
Phone
415-766-3638
Fax
302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer
Mark Goldsmith
Chief Financial Officer
Jack Anders
President - Research and Development
Steve Kelsey
Chief Operating Officer
Margaret Horn
Executive Vice President - Development
Xiaolin Wang

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$7.2B
Revenue (TTM)
$4.6M
Shares Outstanding
165.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.45
EPS
$-3.76
Book Value
$11.09
P/E Ratio
-11.6x
Price/Sales (TTM)
1,566.4
Price/Cash Flow (TTM)
---
Operating Margin
-12,170.11%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.